GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
GRAIL (Nasdaq: GRAL) will report fourth quarter and full year 2025 financial results after market close on Thursday, Feb. 19, 2026.
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) will report fourth quarter and full year 2025 financial results after market close on Thursday, Feb. 19, 2026.
Management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress. According to the company, a live webcast and recorded replay will be available at the investor relations site and open to all.
Positive
- None.
Negative
- None.
Details
News Market Reaction – GRAL
In the trading session that priced this news, GRAL gained 1.57%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Total revenue
- $36.2M
- Q3 2025 total revenue, +26% YoY
- U.S. Galleri revenue
- $32.6M
- Q3 2025, +28% YoY
- Galleri tests sold
- >45,000
- Q3 2025 tests sold, +39% YoY
- Net loss
- $89.0M
- Q3 2025 net loss
- Adjusted EBITDA
- $(71.7)M
- Q3 2025 adjusted EBITDA
- Adjusted gross profit
- $20.0M
- Q3 2025 adjusted gross profit
- Private placement
- $325M
- Capital raised via private placement, reported with Q3 2025
- Cash position
- >$850M
- Cash runway into 2030, as of Q3 2025
Historical Context
-
Filed final PMA module for Galleri multi-cancer early detection test.
-
Announced management presentation at J.P. Morgan Healthcare Conference.
-
Granted 21,570 RSUs to 21 non-executive employees under inducement plan.
-
Planned presentation at Piper Sandler 37th Annual Healthcare Conference.
-
Reported Q3 2025 revenue growth, Galleri expansion, financing, and strong cash.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fourth Quarter and Full Year 2025 Webcast and Conference Call Details
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.
Please register for the live event at https://grail-q4-financial-results-2025.open-exchange.net/
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results-302688442.html
SOURCE GRAIL, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.